Shi Ming, Guo Ning
Department of molecular immunology, Institute of Basic Medical Sciences, Beijing, PR China.
Cancer Treat Rev. 2009 Jun;35(4):328-34. doi: 10.1016/j.ctrv.2008.12.002. Epub 2009 Jan 25.
Alterations in microRNA (miRNA) expression have been associated with tumor suppression or tumorigenesis, metastasis and poor prognosis in human breast cancer. Deregulation of miRNAs is emerging as a major aspect of cancer etiology because their capacity to direct the translation and stability of targeted transcripts can dramatically influence cellular physiology. Some miRNAs were considered to be associated with molecular subtypes of breast cancer and correlated with specific breast cancer clinicopathological factors, such as HER2, estrogen and progesterone receptor level, tumor stage, vascular invasion, or proliferation index. The expression level of miRNAs as suppressors, which can inhibit the expression of tumor promoting genes, is frequently down-regulated in breast cancer. Multiple lines of evidence also demonstrated the involvement of specific miRNAs as oncogenes in breast tumorigenesis. Some miRNAs have been considered to have potential clinical applications as a novel biomarker for breast cancer diagnosis and prognostic factor. Exploitation of the therapeutic potential of RNA interference will be an important task and achieved through the further understanding of the mechanisms of gene regulation by miRNAs.
微小RNA(miRNA)表达的改变与人类乳腺癌的肿瘤抑制、肿瘤发生、转移及不良预后相关。miRNA失调正成为癌症病因学的一个主要方面,因为它们指导靶向转录本翻译和稳定性的能力可显著影响细胞生理学。一些miRNA被认为与乳腺癌的分子亚型相关,并与特定的乳腺癌临床病理因素相关,如HER2、雌激素和孕激素受体水平、肿瘤分期、血管侵犯或增殖指数。作为抑制因子的miRNA的表达水平,其可抑制肿瘤促进基因的表达,在乳腺癌中经常下调。多条证据也证明特定miRNA作为癌基因参与乳腺癌的发生。一些miRNA被认为作为乳腺癌诊断的新型生物标志物和预后因素具有潜在的临床应用价值。开发RNA干扰的治疗潜力将是一项重要任务,这需要通过进一步了解miRNA的基因调控机制来实现。